Delving into the Latest Updates on RSQ-15 with Synapse

Overview

Basic Info

Drug Type

DNA vaccine, Prophylactic vaccine

Synonyms

esx gene family targeting multivalent DNA vaccine (Inovio)

Target

ELF3

Action

modulators

Mechanism

ESX gene modulators

Therapeutic Areas

Infectious Diseases

Active Indication-

Inactive Indication

Tuberculosis

Originator Organization

Inovio Pharmaceuticals, Inc.

Active Organization-

Inactive Organization

Inovio Pharmaceuticals, Inc.

License Organization-

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

ABSTRACT The causative agent of human tuberculosis, Mycobacterium tuberculosis , has a complex lipid-rich diderm envelope, which acts as a major barrier protecting the bacterium against the hostile environment inside the host cells. For the transfer of diverse molecules across this complex cell envelope, M. tuberculosis has a series of general and specialized protein secretion systems, characterized by the SecA general secretion pathway, the twin-arginine translocation pathway, and five specific ESX type VII secretion systems. In this review, we focus on the latter systems, known as ESX-1 to ESX-5, which were first discovered almost 20 years ago during the in silico analysis of the genome sequence of M. tuberculosis H37Rv. Since then, these systems have been the subject of highly dynamic research due to their involvement in several key biological processes and host-pathogen interactions of the tubercle bacilli.

100 Deals associated with RSQ-15

Login to view more data